» Articles » PMID: 21781156

Development of Fulminant Type 1 Diabetes with Thrombocytopenia After Influenza Vaccination: a Case Report

Overview
Journal Diabet Med
Specialty Endocrinology
Date 2011 Jul 26
PMID 21781156
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fulminant Type 1 diabetes was originally reported as idiopathic Type 1 diabetes. Involvement of viral infections in the pathogenesis of fulminant T1D has been suggested, but the development of fulminant Type 1 diabetes after influenza vaccination has not been reported.

Case Report: We report a case of fulminant Type 1 diabetes with thrombocytopenia following influenza vaccination. A 54-year-old man was admitted to hospital with hyperglycaemia and diabetic ketosis. Seven days before admission, he received a seasonal influenza vaccine for the prevention of influenza infection. On admission, blood glucose was 29 mmol/L and HbA1c 40 mmol/mol (5.9%). Fasting and 2-h C-peptide immunoreactivity were <0.0333 nmol/L and 0.0999 nmol/L, respectively. Anti-GAD and anti-IA-2 antibodies were negative, so no autoimmunity seemed to participate in the etiology. ELISPOT assay also showed no association with T cell-mediated autoimmunity. HLA genotypes were consistent with susceptibility to fulminant Type 1 diabetes. After the abrupt onset of diabetes, he showed mild thrombocytopenia, which has been observed for approximately 5 years after diabetes development.

Conclusion: This is the first description of fulminant Type 1 diabetes after influenza vaccination. Our observation raises the possibility that influenza vaccination might trigger this condition via the TLR7 pathway.

Citing Articles

Association Between Influenza Vaccine and Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.

Liu Z, Wang J, Lu Z, Xu Y, Du J, Han J Vaccines (Basel). 2024; 12(11).

PMID: 39591200 PMC: 11599087. DOI: 10.3390/vaccines12111298.


Anti-GAD antibody-positive fulminant type 1 diabetes developed following SARS-CoV-2 vaccination.

Izumi T, Takahashi H, Takahashi H Diabetol Int. 2023; 14(4):422-426.

PMID: 37781472 PMC: 10533421. DOI: 10.1007/s13340-023-00648-8.


Fulminant type 1 diabetes developed after influenza split vaccination.

Sawamura T, Karashima S, Ohmori A, Sawada K, Aono D, Kometani M Endocrinol Diabetes Metab Case Rep. 2023; 2023(2).

PMID: 37140990 PMC: 10337240. DOI: 10.1530/EDM-22-0342.


New-onset atypical fulminant type 1 diabetes after COVID-19 vaccination: A case report.

Kobayashi T, Yakou F, Saburi M, Hirose A, Akaoka H, Hirota Y Clin Case Rep. 2022; 10(10):e6473.

PMID: 36267825 PMC: 9576963. DOI: 10.1002/ccr3.6473.


Type 1 diabetes mellitus following COVID-19 RNA-based vaccine.

Sakurai K, Narita D, Saito N, Ueno T, Sato R, Niitsuma S J Diabetes Investig. 2022; 13(7):1290-1292.

PMID: 35220662 PMC: 9114989. DOI: 10.1111/jdi.13781.